Chemically deposited In2S3–Ag2S layers to obtain AgInS2 thin films by thermal annealing.

AgInS2 thin films were obtained by the annealing of chemical bath deposited In2S3–Ag2S layers at 400 ◦C in N2 for 1 h. According to the XRD and EDX results the chalcopyrite structure of AgInS2 has been obtained. These films have an optical band gap, Eg, of 1.86 eV and an electrical conductivity value of 1.2 × 10−3 ( cm)−1

Purification of supercritical-fluid carotenoid-rich extracts by hydrophobic interaction chromatography

Supercritical fluid extraction (SFE) has been widely used for extracting several valuable phytochemicals, including carotenoids. However, there is a scarcity of works dealing with the purification of SFE extracts. The aim of this work was to assess the feasibility and efficiency of a hydrophobic interaction chromatography (HIC) protocol for purifying carotenoid-rich extracts obtained by SFE. Initial batch experiments were carried out to calculate the resin adsorption capacity and adsorption kinetics. Subsequent runs were performed in a manually-packed chromatographic column, using the Amberlite XAD-1180N resin, where breakthrough curves and adsorption isotherms were obtained and fitted to the Langmuir model. The antioxidant activity and carotenoid degradation rates were monitored throughout the processes. In batch, the resin presented a maximum carotenoid adsorption capacity of 1.89 μg/mg, while in column, this value increased to 10.4 μg/mg. The global carotenoid adsorption rate was 93.3% and the elution rate, 94.7%, resulting in a global recovery of 88.4% for total carotenoids and 92.1% for carotenes. The Langmuir model fitted well the experimental data. Analysis of the extracts demonstrated that a 5.5-fold reduction in extract mass was achieved, accompanied by a 4.7-fold and 2.1-fold increase in carotenoid concentration and antioxidant activity, respectively. This work presents a novel process based on preparative HIC for the purification of carotenoid extracts and provides a fundamental understanding on process performance. It is potentially scalable and can be implemented in extraction and purification of carotenoids from natural sources, as an alternative to their production through chemical synthesis

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

EDUCACIÓN AMBIENTAL Y SOCIEDAD. SABERES LOCALES PARA EL DESARROLLO Y LA SUSTENTABILIDAD

Este texto contribuye al análisis científico de varias áreas del conocimiento como la filosofía social, la patología, la educación para el cuidado del medio ambiente y la sustentabilidad que inciden en diversas unidades de aprendizaje de la Licenciatura en Educación para la Salud y de la Maestría en Sociología de la SaludLas comunidades indígenas de la sierra norte de Oaxaca México, habitan un territorio extenso de biodiversidad. Sin que sea una área protegida y sustentable, la propia naturaleza de la región ofrece a sus visitantes la riqueza de la vegetación caracterizada por sus especies endémicas que componen un paisaje de suma belleza

Modelación de un tratamiento avanzado de aguas residuales, provenientes de una planta de envasado, usando las metodologías de análisis de superficie de respuesta (ASR) y de redes neuronales (RNA)

El agua residual estudiada fue obtenida de una planta productora de latas, localizada en el centro de la República Mexicana. Esta agua residual fue caracterizada y tratada a nivel laboratorio y planta piloto usando procesos de coagulación y floculación. Tres coagulantes y dos floculantes fueron usados en seis combinaciones y un diseño factorial, así como un análisis de superficie de respuesta (ASR) fueron llevados a cabo para explorar los efectos de pH, concentraciones de coagulante y floculante y velocidad de agitación. Del mismo modo pruebas de sedimentación en columna fueron llevadas a cabo, a las mejores condiciones de operación, para determinar el tiempo de detención para la planta piloto. Estas condiciones fueron utilizadas para construir una planta piloto para tratar 15.14 L/min, la cual incluye una membrana de ósmosis inversa (OI). En la prueba de jarras, las mejores condiciones de remoción UNT con cero turbidez fueron alcanzadas por la combinación de A12(SO.),-NALCO 9907, a l00 min-1 Y pH ácido. En la planta piloto fue requerido un tiempo de detención de 2 horas para remover el l00 % de los sólidos suspendidos en el tanque de sedimentación. La unidad de OI permitió el incremento de remoción de los sólidos totales disueltos a 96.1 % permitiendo una recuperación máxima de agua residual de casi 72 %. Los datos de la unidad de OI fueron exitosamente modelados mediante redes neuroua1es artificiales (ANN). Una red de custro capas alimentada hacia adelante con un algoritmo de propagación hacia atrás fue usada para entrenar todos los modelos de RNA. Los datos esperados y experimentales fueron bien correlacionados y fue alcanzado un coeficiente de determinación de 0.99